

Marten Trendelenburg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/974717/publications.pdf>

Version: 2024-02-01

116
papers

2,669
citations

212478

28
h-index

242451

47
g-index

146
all docs

146
docs citations

146
times ranked

3587
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Serum interferon- λ levels and IFN type I-stimulated genes score perform equally to assess systemic lupus erythematosus disease activity. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 901-903. | 0.5 | 11 |
| 2 | Cutaneous leukocytoclastic vasculitis secondary to COVID-19 infection leading to extensive skin necrosis. <i>Clinics in Dermatology</i> , 2022, 40, 397-401. | 0.8 | 9 |
| 3 | Prediction of Acute COPD Exacerbation in the Swiss Multicenter COPD Cohort Study (TOPDOCS) by Clinical Parameters, Medication Use, and Immunological Biomarkers. <i>Respiration</i> , 2022, 101, 441-454. | 1.2 | 4 |
| 4 | Perception of physicians and nursing staff members regarding outside versus bedside ward rounds: ancillary analysis of the randomised BEDSIDE-OUTSIDE trial. <i>Swiss Medical Weekly</i> , 2022, 152, w30112. | 0.8 | 0 |
| 5 | Anti-C1q Autoantibodies: Standard Quantification and Innovative ELISA. <i>Methods in Molecular Biology</i> , 2021, 2227, 107-114. | 0.4 | 4 |
| 6 | Autoantibodies against complement component C1q in systemic lupus erythematosus. <i>Clinical and Translational Immunology</i> , 2021, 10, e1279. | 1.7 | 15 |
| 7 | Association of mannose-binding lectin, ficolin-2 and immunoglobulin concentrations with future exacerbations in patients with chronic obstructive pulmonary disease: secondary analysis of the randomized controlled REDUCE trial. <i>Respiratory Research</i> , 2021, 22, 227. | 1.4 | 3 |
| 8 | Variants Affecting the C-Terminal Tail of UNC93B1 Are Not a Common Risk Factor for Systemic Lupus Erythematosus. <i>Genes</i> , 2021, 12, 1268. | 1.0 | 0 |
| 9 | Effect of Bedside Compared With Outside the Room Patient Case Presentation on Patients' Knowledge About Their Medical Care. <i>Annals of Internal Medicine</i> , 2021, 174, 1282-1292. | 2.0 | 13 |
| 10 | Recombinant human C1 esterase inhibitor (conestat alfa) in the prevention of severe SARS-CoV-2 infection in hospitalized patients with COVID-19: A structured summary of a study protocol for a randomized, parallel-group, open-label, multi-center pilot trial (PROTECT-COVID-19). <i>Trials</i> , 2021, 22, 1. | 0.7 | 81 |
| 11 | Functional Activity of the Complement System in Hospitalized COVID-19 Patients: A Prospective Cohort Study. <i>Frontiers in Immunology</i> , 2021, 12, 765330. | 2.2 | 15 |
| 12 | Epitope-Specific Anti-C1q Autoantibodies in Systemic Lupus Erythematosus. <i>Frontiers in Immunology</i> , 2021, 12, 761395. | 2.2 | 5 |
| 13 | Preclinical to clinical translation of cenerimod, a novel S1P ₁ receptor modulator, in systemic lupus erythematosus. <i>RMD Open</i> , 2020, 6, e001261. | 1.8 | 10 |
| 14 | Complement C1q Enhances Primary Hemostasis. <i>Frontiers in Immunology</i> , 2020, 11, 1522. | 2.2 | 13 |
| 15 | Case Report "Secondary Antibody Deficiency Due to Endogenous Hypercortisolism. <i>Frontiers in Immunology</i> , 2020, 11, 1435. | 2.2 | 3 |
| 16 | Local and Systemic Concentrations of Pattern Recognition Receptors of the Lectin Pathway of Complement in a Cohort of Patients With Interstitial Lung Diseases. <i>Frontiers in Immunology</i> , 2020, 11, 562564. | 2.2 | 8 |
| 17 | P138...Preclinical and clinical characterization of cenerimod, a potent, selective, and orally active sphingosine-1-phosphate receptor 1 modulator in SLE. , 2020, , . | | 1 |
| 18 | O38...Preclinical and clinical characterization of cenerimod, a potent, selective, and orally active sphingosine-1-phosphate receptor 1 modulator in SLE. , 2020, , . | | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | P16â€¦The combined type-I interferon and neutrophil gene scores identify highly active systemic lupus erythematosus patients and performed better than classical serological markers. , 2020, , . | | 0 |
| 20 | Treatment of COVID-19 With Conestat Alfa, a Regulator of the Complement, Contact Activation and Kallikrein-Kinin System. <i>Frontiers in Immunology</i> , 2020, 11, 2072. | 2.2 | 67 |
| 21 | Identification of highly active systemic lupus erythematosus by combined type I interferon and neutrophil gene scores vs classical serologic markers. <i>Rheumatology</i> , 2020, 59, 3468-3478. | 0.9 | 18 |
| 22 | A Randomized Trial of Recombinant Human C1-Esterase-Inhibitor in the Prevention of Contrast-Induced Kidney Injury. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 833-842. | 1.1 | 10 |
| 23 | No association of complement mannose-binding lectin deficiency with cardiovascular disease in patients with Systemic Lupus Erythematosus. <i>Scientific Reports</i> , 2020, 10, 3693. | 1.6 | 4 |
| 24 | Anti-apolipoprotein A-1 autoantibodies correlate with disease activity in systemic lupus erythematosus. <i>Rheumatology</i> , 2019, 59, 534-544. | 0.9 | 3 |
| 25 | SaO039RECOMBINANT HUMAN C1 ESTERASE INHIBITOR (CONESTAT ALFA) IN THE PREVENTION OF CONTRAST-INDUCED NEPHROPATHY IN HIGH-RISK PATIENTS (PROTECT): A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND SINGLE-CENTER TRIAL. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, . | 0.4 | 0 |
| 26 | Ficolin-3 Deficiency Is Associated with Disease and an Increased Risk of Systemic Lupus Erythematosus. <i>Journal of Clinical Immunology</i> , 2019, 39, 421-429. | 2.0 | 28 |
| 27 | Role of lectin pathway complement proteins and genetic variants in organ damage and disease severity of systemic sclerosis: a cross-sectional study. <i>Arthritis Research and Therapy</i> , 2019, 21, 76. | 1.6 | 10 |
| 28 | Susceptibility of BAFF-var allele carriers to severe SLE with occurrence of lupus nephritis. <i>BMC Nephrology</i> , 2019, 20, 430. | 0.8 | 11 |
| 29 | Anti-C1q Antibodies as Occurring in Systemic Lupus Erythematosus Could Be Induced by an Epstein-Barr Virus-Derived Antigenic Site. <i>Frontiers in Immunology</i> , 2019, 10, 2619. | 2.2 | 22 |
| 30 | Binding of von Willebrand Factor to Complement C1q Decreases the Phagocytosis of Cholesterol Crystals and Subsequent IL-1 Secretion in Macrophages. <i>Frontiers in Immunology</i> , 2019, 10, 2712. | 2.2 | 13 |
| 31 | Association of antibodies against myelin and neuronal antigens with neuroinflammation in systemic lupus erythematosus. <i>Rheumatology</i> , 2019, 58, 908-913. | 0.9 | 19 |
| 32 | Prevalence, persistence and clinical correlations of classic and novel antiphospholipid antibodies in systemic lupus erythematosus. <i>Rheumatology</i> , 2018, 57, 1350-1357. | 0.9 | 28 |
| 33 | Complement activation products in acute heart failure: Potential role in pathophysiology, responses to treatment and impacts on long-term survival. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2018, 7, 348-357. | 0.4 | 7 |
| 34 | Immune complexes containing serum B-cell activating factor and immunoglobulin G correlate with disease activity in systemic lupus erythematosus. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 54-64. | 0.4 | 12 |
| 35 | The heart in systemic lupus erythematosus â€“ A comprehensive approach by cardiovascular magnetic resonance tomography. <i>PLoS ONE</i> , 2018, 13, e0202105. | 1.1 | 39 |
| 36 | Autoantibodies Against Albumin in Patients With Systemic Lupus Erythematosus. <i>Frontiers in Immunology</i> , 2018, 9, 2090. | 2.2 | 16 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | The Lectin Pathway of Complement in Myocardial Ischemia/Reperfusion Injury—Review of Its Significance and the Potential Impact of Therapeutic Interference by C1 Esterase Inhibitor. <i>Frontiers in Immunology</i> , 2018, 9, 1151. | 2.2 | 39 |
| 38 | The Lectin Pathway of Complement Activation in Patients with Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2018, 45, 1136-1144. | 1.0 | 36 |
| 39 | Serum calcification propensity is independently associated with disease activity in systemic lupus erythematosus. <i>PLoS ONE</i> , 2018, 13, e0188695. | 1.1 | 12 |
| 40 | Association of Lectin Pathway Protein Levels and Genetic Variants Early after Injury with Outcomes after Severe Traumatic Brain Injury: A Prospective Cohort Study. <i>Journal of Neurotrauma</i> , 2017, 34, 2560-2566. | 1.7 | 18 |
| 41 | Cathepsin S inhibition suppresses autoimmune-triggered inflammatory responses in macrophages. <i>Biochemical Pharmacology</i> , 2017, 146, 151-164. | 2.0 | 26 |
| 42 | Primary intestinal lymphangiectasia in an elderly female patient. <i>Medicine (United States)</i> , 2017, 96, e7729. | 0.4 | 9 |
| 43 | Association of lectin pathway protein levels and genetic variants early after injury with outcomes after severe traumatic brain injury. A prospective cohort study. <i>Molecular Immunology</i> , 2017, 89, 212-213. | 1.0 | 0 |
| 44 | Impact of disease activity on health-related quality of life in systemic lupus erythematosus — a cross-sectional analysis of the Swiss Systemic Lupus Erythematosus Cohort Study (SSCS). <i>BMC Immunology</i> , 2017, 18, 17. | 0.9 | 42 |
| 45 | Anti-C1q autoantibodies from patients with systemic lupus erythematosus induce C1q production by macrophages. <i>Journal of Leukocyte Biology</i> , 2017, 101, 481-491. | 1.5 | 10 |
| 46 | TOO11BAFF AND IMMUNE COMPLEXES CONSISTING OF BAFF AND IMMUNOGLOBULIN G ARE ASSOCIATED WITH RENAL INVOLVEMENT AND DISEASE ACTIVITY IN SLE. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, iii82-iii82. | 0.4 | 0 |
| 47 | A prediction model for exacerbations in patients with COPD generated in a Swiss multicenter COPD cohort study (TOPDOCS). , 2017, , . | | 0 |
| 48 | Anti-C1q autoantibodies are linked to autoimmune thyroid disorders in pregnant women. <i>Clinical and Experimental Immunology</i> , 2016, 186, 10-17. | 1.1 | 4 |
| 49 | Von Willebrand Factor Interacts with Surface-Bound C1q and Induces Platelet Rolling. <i>Journal of Immunology</i> , 2016, 197, 3669-3679. | 0.4 | 25 |
| 50 | Association of lectin pathway proteins with intra-abdominal <i>Candida</i> infection in high-risk surgical intensive-care unit patients. A prospective cohort study within the fungal infection network of Switzerland. <i>Journal of Infection</i> , 2016, 72, 377-385. | 1.7 | 6 |
| 51 | Anti-C1q Autoantibodies from Systemic Lupus Erythematosus Patients Induce a Proinflammatory Phenotype in Macrophages. <i>Journal of Immunology</i> , 2016, 196, 2063-2074. | 0.4 | 28 |
| 52 | Interferon-lambda-genotype GG and IgG2 are predictors for frequent COPD exacerbations in a Swiss multicenter COPD cohort study (TOPDOCS). , 2016, , . | | 0 |
| 53 | FRIO390—Health-Related Quality of Life in Swiss Patients with Systemic Lupus Erythematosus — A Cross-Sectional Analysis Within the Swiss Systemic Lupus Erythematosus Cohort Study (SSCS). <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 568.2-568. | 0.5 | 0 |
| 54 | Mannose-binding lectin protein and its association to clinical outcomes in COPD: a longitudinal study. <i>Respiratory Research</i> , 2015, 16, 150. | 1.4 | 18 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Anti-C1q Antibodies as a Follow-Up Marker in SLE Patients. PLoS ONE, 2015, 10, e0123572. | 1.1 | 49 |
| 56 | Prognostic value of anti-CRP antibodies in lupus nephritis in long-term follow-up. Arthritis Research and Therapy, 2015, 17, 371. | 1.6 | 20 |
| 57 | Prevalence of vascular disease in systemic lupus erythematosus compared with type-1 diabetes mellitus: A cross-sectional study of two cohorts. Lupus, 2015, 24, 58-65. | 0.8 | 21 |
| 58 | Anti-C1q autoantibodies from systemic lupus erythematosus patients activate the complement system via both the classical and lectin pathways. Clinical Immunology, 2015, 160, 180-187. | 1.4 | 33 |
| 59 | Clinical presentation of human C1q deficiency: How much of a lupus?. Molecular Immunology, 2015, 67, 3-11. | 1.0 | 86 |
| 60 | Complement activation in patients with neuromyelitis optica. Journal of Neuroimmunology, 2014, 274, 185-191. | 1.1 | 54 |
| 61 | The Swiss Systemic lupus erythematosus Cohort Study (SSCS) â€” cross-sectional analysis of clinical characteristics and treatments across different medical disciplines in Switzerland. Swiss Medical Weekly, 2014, 144, w13990. | 0.8 | 31 |
| 62 | Critical incidents in a tertiary care clinic for internal medicine. BMC Research Notes, 2013, 6, 276. | 0.6 | 13 |
| 63 | Anti-C1q antibodies as a follow-up marker in SLE patients. Molecular Immunology, 2013, 56, 274. | 1.0 | 0 |
| 64 | Impact of Mannose-Binding Lectin Deficiency on Radiocontrast-Induced Renal Dysfunction. BioMed Research International, 2013, 2013, 1-8. | 0.9 | 6 |
| 65 | Association between Low Levels of Mannan-Binding Lectin and Markers of Autoimmune Thyroid Disease in Pregnancy. PLoS ONE, 2013, 8, e81755. | 1.1 | 3 |
| 66 | Low Levels of Mannan-Binding Lectin or Ficolins Are Not Associated with an Increased Risk of Cytomegalovirus Disease in HIV-Infected Patients. PLoS ONE, 2013, 8, e51983. | 1.1 | 8 |
| 67 | A Trial of Complement Inhibition in a Patient with Cryoglobulin-Induced Glomerulonephritis. Case Reports in Nephrology and Urology, 2012, 2, 38-45. | 1.5 | 6 |
| 68 | Identification of a major linear C1q epitope allows detection of systemic lupus erythematosus anti-C1q antibodies by a specific peptide-based enzyme-linked immunosorbent assay. Arthritis and Rheumatism, 2012, 64, 3706-3714. | 6.7 | 37 |
| 69 | Identification of critical core amino acids of a major linear C1q epitope recognized by SLE auto-antibodies. Immunobiology, 2012, 217, 1176. | 0.8 | 1 |
| 70 | Impact of mannose-binding lectin deficiency on radiocontrast-induced renal dysfunction: a post-hoc analysis of a multicenter randomized controlled trial. BMC Nephrology, 2012, 13, 99. | 0.8 | 4 |
| 71 | Serum cytokine profile in patients with active lupus nephritis. Cytokine, 2012, 60, 410-416. | 1.4 | 76 |
| 72 | MBL serum levels in patients with sepsis correlate with thyroid function but not with outcome. Clinical Immunology, 2012, 144, 80-82. | 1.4 | 5 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 73 | Anti-C1q antibodies as a diagnostic marker of proliferative lupus nephritis: Comment on the article by Katsumata et al. <i>Arthritis and Rheumatism</i> , 2012, 64, 324-325. | 6.7 | 3 |
| 74 | Cryoglobulinemia and Chronic HCV Infection: An Evolving Story. , 2012, , 79-83. | | 0 |
| 75 | The Complement System in Cryoglobulinemia. , 2012, , 85-89. | | 0 |
| 76 | Mannose-binding lectinâ€™the forgotten molecule?. <i>Nature Medicine</i> , 2011, 17, 1547-1548. | 15.2 | 7 |
| 77 | Mannose-Binding Lectin Deficiency Is Associated With Smaller Infarction Size and Favorable Outcome in Ischemic Stroke Patients. <i>PLoS ONE</i> , 2011, 6, e21338. | 1.1 | 77 |
| 78 | The role of functional Mannose-binding lectin deficiency in contrast-induced nephropathy. <i>Molecular Immunology</i> , 2011, 48, 1717-1718. | 1.0 | 0 |
| 79 | Identification of epitopes on the collagen-like region of C1q recognized by serum antibodies from patients with lupus erythematosus. <i>Molecular Immunology</i> , 2011, 48, 1720-1721. | 1.0 | 0 |
| 80 | Anti-C1q autoantibodies do not correlate with the occurrence or severity of experimental lupus nephritis. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 1220-1228. | 0.4 | 20 |
| 81 | Three cases of primary small vessel vasculitis of the skeletal muscle-an own entity. <i>BMJ Case Reports</i> , 2011, 2011, bcr0820114631-bcr0820114631. | 0.2 | 8 |
| 82 | Mannose-binding lectin levels and major infections in a cohort of very long-term survivors after allogeneic stem cell transplantation. <i>Haematologica</i> , 2010, 95, 1389-1396. | 1.7 | 15 |
| 83 | Primary cytomegalovirus infection with accompanying <i>Pneumocystis jiroveci</i> pneumonia in a patient with large-vessel vasculitis. <i>Infection</i> , 2010, 38, 331-334. | 2.3 | 9 |
| 84 | Anti-C1q autoantibodies do not correlate with the occurrence or severity of experimental lupus nephritis. <i>Molecular Immunology</i> , 2010, 47, 2208-2208. | 1.0 | 0 |
| 85 | The production of mannan-binding lectin is dependent upon thyroid hormones regardless of the genotype: A cohort study of 95 patients with autoimmune thyroid disorders. <i>Clinical Immunology</i> , 2010, 136, 123-129. | 1.4 | 20 |
| 86 | A patient with SLE-associated thrombotic microangiopathy and non-neutralizing antibodies against ADAMTS13. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 1720-1722. | 0.4 | 8 |
| 87 | Influence of functional deficiency of complement mannose-binding lectin on outcome of patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. <i>European Heart Journal</i> , 2010, 31, 1181-1187. | 1.0 | 53 |
| 88 | Autoantibodies against Complement C1q Specifically Target C1q Bound on Early Apoptotic Cells. <i>Journal of Immunology</i> , 2009, 183, 3512-3521. | 0.4 | 67 |
| 89 | Autoantibodies against C1q in Systemic Lupus Erythematosus Are Antigen-Driven. <i>Journal of Immunology</i> , 2009, 183, 8225-8231. | 0.4 | 50 |
| 90 | Autoantibodies against complement C1q correlate with the thyroid function in patients with autoimmune thyroid disease. <i>Clinical and Experimental Immunology</i> , 2008, 153, 96-101. | 1.1 | 22 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 91 | Autoantibodies against complement C1q in acute post-streptococcal glomerulonephritis. <i>Clinical Immunology</i> , 2008, 128, 409-414. | 1.4 | 21 |
| 92 | Antinucleosome Antibodies as a Marker of Active Proliferative Lupus Nephritis. <i>American Journal of Kidney Diseases</i> , 2008, 51, 624-629. | 2.1 | 44 |
| 93 | Autoantibodies against complement C1q specifically target C1q bound on early apoptotic cells. <i>Molecular Immunology</i> , 2008, 45, 4118. | 1.0 | 1 |
| 94 | Autoantibodies against complement C1q in acute post-streptococcal glomerulonephritis. <i>Molecular Immunology</i> , 2008, 45, 4174. | 1.0 | 0 |
| 95 | Acute Liver Failure in Two Patients with Regular Alcohol Consumption Ingesting Paracetamol at Therapeutic Dosage. <i>Digestion</i> , 2007, 75, 232-237. | 1.2 | 22 |
| 96 | Rituximab in a Patient With Hyper-IgE Syndrome. <i>Archives of Dermatology</i> , 2007, 143, 799. | 1.7 | 7 |
| 97 | Association Between Mannose-Binding Lectin Deficiency and Cytomegalovirus Infection After Kidney Transplantation. <i>Transplantation</i> , 2007, 83, 359-362. | 0.5 | 81 |
| 98 | Meningococcal disease in a kidney transplant recipient with mannose-binding lectin deficiency. <i>Transplant Infectious Disease</i> , 2007, 9, 214-218. | 0.7 | 9 |
| 99 | Complement inhibition by anti-C5 antibodies—from bench to bedside and back again. <i>Swiss Medical Weekly</i> , 2007, 137, 413-7. | 0.8 | 5 |
| 100 | Anti-C1q antibodies in hepatitis C virus infection. <i>Clinical and Experimental Immunology</i> , 2006, 145, 308-312. | 1.1 | 43 |
| 101 | High prevalence of anti-C1q antibodies in biopsy-proven active lupus nephritis. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 3115-3121. | 0.4 | 164 |
| 102 | Clinical Value of Autoantibodies Against C1q in Children With Glomerulonephritis. <i>Pediatrics</i> , 2006, 117, 1663-1668. | 1.0 | 35 |
| 103 | Antibodies against C1q in patients with systemic lupus erythematosus. <i>Seminars in Immunopathology</i> , 2005, 27, 276-285. | 4.0 | 81 |
| 104 | The Role of Complement in Cryoglobulin-Induced Immune Complex Glomerulonephritis. <i>Journal of Immunology</i> , 2005, 175, 6909-6914. | 0.4 | 57 |
| 105 | Monocytosis and accelerated activation of lymphocytes in C1q-deficient autoimmune-prone mice. <i>Immunology</i> , 2004, 113, 80-88. | 2.0 | 19 |
| 106 | Autoantibodies against complement receptor 1 (CD35) in SLE, liver cirrhosis and HIV-infected patients. <i>Clinical and Experimental Immunology</i> , 2003, 131, 174-181. | 1.1 | 11 |
| 107 | Cryoglobulins in chronic hepatitis C virus infection. <i>Clinical and Experimental Immunology</i> , 2003, 133, 153-155. | 1.1 | 29 |
| 108 | Cryoglobulin/albumin complexes in a patient with severe autoimmune syndrome. <i>Scandinavian Journal of Rheumatology</i> , 2003, 32, 367-373. | 0.6 | 6 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 109 | Anti-C1q antibodies may help in diagnosing a renal flare in lupus nephritis. American Journal of Kidney Diseases, 2001, 37, 490-498. | 2.1 | 168 |
| 110 | Disseminated scabies evolving in a patient undergoing induction chemotherapy for acute myeloblastic leukaemia. Annals of Hematology, 2001, 80, 116-118. | 0.8 | 2 |
| 111 | “Altered immunity syndrome”, a distinct entity in long-term bone marrow transplantation survivors?. Bone Marrow Transplantation, 2001, 28, 1175-1176. | 1.3 | 15 |
| 112 | Hepatitis Virus-Related and Ethanol-Induced Chronic Liver Disease with or without Cryoglobulins - Is There a Difference Concerning Clinical or Laboratory Manifestation?. Infection, 1999, 27, 248-251. | 2.3 | 5 |
| 113 | Lack of occurrence of severe lupus nephritis among anti-C1q autoantibody-negative patients. Arthritis and Rheumatism, 1999, 42, 187-188. | 6.7 | 121 |
| 114 | Hypocomplementemic urticarial vasculitis or systemic lupus erythematosus?. American Journal of Kidney Diseases, 1999, 34, 745-751. | 2.1 | 42 |
| 115 | Cryoglobulins are not essential. Annals of the Rheumatic Diseases, 1998, 57, 3-5. | 0.5 | 41 |
| 116 | A New Steroid-Eluting Screw-In Electrode. PACE - Pacing and Clinical Electrophysiology, 1994, 17, 1134-1142. | 0.5 | 20 |